Grandfield & Dodd LLC Purchases Shares of 36,628 Regeneron Pharmaceuticals, Inc. $REGN

Grandfield & Dodd LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 36,628 shares of the biopharmaceutical company's stock, valued at approximately $22,839,000. Regeneron Pharmaceuticals accounts for approximately 1.2% of Grandfield & Dodd LLC's holdings, making the stock its 26th biggest holding.

Several other large investors also recently made changes to their positions in REGN. WPG Advisers LLC raised its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $26,000. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Trust Co. of Vermont bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $29,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wall Street Zen raised Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Citigroup lifted their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a "buy" rating in a research note on Thursday, April 23rd. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating for the company in a research report on Monday, May 18th. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a "hold" rating in a research report on Wednesday, July 29th. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $801.70.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director owned 603 shares of the company's stock, valued at approximately $482,400. This represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $805.93 on Tuesday. The stock has a market capitalization of $82.98 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 1.37 and a beta of 0.21. The business has a 50-day moving average of $679.69 and a 200-day moving average of $714.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals's revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.81 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source